This observation suggests β2M levels in CLL patients reflect pathological JAK‐mediated cytokine activity, although the cellular origin of β2M is unclear and may not necessarily be from CLL cells. This evidence concerns the gene B2M and B-cell chronic lymphocytic leukemia.